BIOMARIN PHARMACEUTICAL INC Additional Paid in Capital, Common Stock
BIOMARIN PHARMACEUTICAL INC (BMRN) had Additional Paid in Capital, Common Stock of $6.04 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $6.04B.
- 2026-03-31: Additional Paid in Capital, Common Stock $5.97B.
- 2025-12-31: Additional Paid in Capital, Common Stock $5.96B.
- 2025-09-30: Additional Paid in Capital, Common Stock $5.90B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $6.04B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $5.97B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $5.96B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $5.90B 10-Q · filed 2025-10-28 |
| 2025-06-30 | $5.85B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $5.79B 10-Q · filed 2025-05-02 |
| 2024-12-31 | $5.80B 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.74B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $5.70B 10-Q · filed 2024-08-05 |
| 2024-03-31 | $5.62B 10-Q · filed 2024-04-26 |
| 2023-12-31 | $5.61B 10-K · filed 2025-02-24 |
| 2023-09-30 | $5.54B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $5.49B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $5.42B 10-Q · filed 2023-04-28 |
| 2022-12-31 | $5.40B 10-K · filed 2024-02-26 |
| 2022-09-30 | $5.34B 10-Q · filed 2022-10-28 |
| 2022-06-30 | $5.27B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $5.21B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $5.19B 10-K · filed 2023-02-27 |
| 2021-09-30 | $5.13B 10-Q · filed 2021-10-29 |
| 2021-06-30 | $5.08B 10-Q · filed 2021-07-30 |
| 2021-03-31 | $5.01B 10-Q · filed 2021-04-30 |
| 2020-12-31 | $4.99B 10-K · filed 2022-02-25 |
| 2020-09-30 | $4.94B 10-Q · filed 2020-11-06 |
| 2020-06-30 | $4.89B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $4.85B 10-Q · filed 2020-05-01 |
| 2019-12-31 | $4.83B 10-K · filed 2021-02-26 |
| 2019-09-30 | $4.78B 10-Q/A · filed 2019-11-04 |
| 2019-06-30 | $4.74B 10-Q · filed 2019-08-02 |
| 2019-03-31 | $4.68B 10-Q · filed 2019-04-29 |
| 2018-12-31 | $4.67B 10-K · filed 2020-02-27 |
| 2018-09-30 | $4.62B 10-Q · filed 2018-10-26 |
| 2018-06-30 | $4.58B 10-Q · filed 2018-08-03 |
| 2018-03-31 | $4.51B 10-Q · filed 2018-04-27 |
| 2017-12-31 | $4.48B 10-K · filed 2019-02-28 |
| 2017-09-30 | $4.44B 10-Q · filed 2017-10-31 |
| 2017-06-30 | $4.40B 10-Q · filed 2017-08-02 |
| 2017-03-31 | $4.31B 10-Q · filed 2017-05-04 |
| 2016-12-31 | $4.29B 10-K · filed 2018-02-26 |
| 2016-09-30 | $4.23B 10-Q · filed 2016-11-03 |
| 2016-06-30 | $3.46B 10-Q · filed 2016-08-08 |
| 2016-03-31 | $3.41B 10-Q · filed 2016-05-02 |
| 2015-12-31 | $3.41B 10-K · filed 2017-02-27 |
| 2015-09-30 | $3.37B 10-Q · filed 2015-11-02 |
| 2015-06-30 | $3.34B 10-Q · filed 2015-08-05 |
| 2015-03-31 | $3.31B 10-Q · filed 2015-05-05 |
| 2014-12-31 | $2.36B 10-K · filed 2016-02-29 |
| 2014-09-30 | $2.28B 10-Q · filed 2014-10-28 |
| 2014-06-30 | $2.25B 10-Q · filed 2014-07-31 |
| 2014-03-31 | $2.21B 10-Q · filed 2014-05-02 |
| 2013-12-31 | $2.06B 10-K · filed 2015-03-02 |
| 2013-09-30 | $1.93B 10-Q · filed 2013-10-28 |
| 2013-06-30 | $1.86B 10-Q · filed 2013-07-29 |
| 2013-03-31 | $1.83B 10-Q · filed 2013-04-29 |
| 2012-12-31 | $1.56B 10-K · filed 2014-02-26 |
| 2012-09-30 | $1.51B 10-Q · filed 2012-10-29 |
| 2012-06-30 | $1.48B 10-Q · filed 2012-08-02 |
| 2012-03-31 | $1.22B 10-Q · filed 2012-04-30 |
| 2011-12-31 | $1.20B 10-K · filed 2013-02-26 |
| 2011-09-30 | $1.18B 10-Q · filed 2011-10-31 |
| 2011-06-30 | $1.12B 10-Q · filed 2011-08-01 |
| 2011-03-31 | $1.10B 10-Q · filed 2011-04-29 |
| 2010-12-31 | $1.09B 10-K · filed 2012-02-22 |
| 2010-09-30 | $948.39M 10-Q · filed 2010-10-29 |
| 2010-06-30 | $931.36M 10-Q · filed 2010-08-04 |
| 2009-12-31 | $899.95M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |